FluGen, Inc. is a biotechnology company focused on developing a more effective vaccine to fight influenza and respiratory diseases. The company's flagship product, M2SR, is an intranasal, supra seasonal flu vaccine designed to stimulate mucosal, humoral, and cellular immunity. This vaccine shows promise based on preclinical and clinical evidence, and it aims to provide broader and longer-lasting protection compared to traditional flu vaccines. FluGen's long-term research and development plans include leveraging the M2SR Vaccine Platform for potential applications against other respiratory diseases, including SARS-CoV-2, the virus that causes COVID-19, and Respiratory Syncytial Virus (RSV). The company primarily serves the healthcare sector, targeting both public health organizations and private healthcare providers. FluGen operates in the global biotechnology market, utilizing a business model that focuses on research and development, clinical trials, and eventual commercialization of its vaccine products. Revenue is generated through partnerships, grants, and future sales of its vaccines.

Keywords: intranasal vaccine, supra seasonal, influenza, respiratory diseases, M2SR, mucosal immunity, humoral immunity, cellular immunity, SARS-CoV-2, RSV.